INDICATIONS: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Red translucent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For the treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. Caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 21 September 2001: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Translucent red suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For the treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. Caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 21 September 2001: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Translucent red suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
INDICATIONS: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Red translucent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
INDICATIONS: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Red translucent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
INDICATIONS: For the treatment of: (1) Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. As first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). INDICATIONS AS AT 29 February 2008: CAELYX, as monotherapy, is indicated for the treatment of metastatic breast cancer. CAELYX is also indicated for the treatment of: Advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. CAELYX may be used as first-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). Caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.
How to take it
The way to take this medicine is: Intravenous.
This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
Store at 2 to 8 degrees Celsius
Do not Freeze
Refrigerate
Shelf lifetime is 20 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Red translucent suspension
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
Support for this browser is being discontinued
Support for this browser is being discontinued for this site
Internet Explorer 11 and lower
We currently support Microsoft Edge, Chrome, Firefox and Safari. For more information, please visit the links below: